EasyCheck360® is a non-invasive blood test designed to detect cancer early by identifying Circulating Tumor Cells (CTCs). These cells are only found in individuals with cancer and are not present in people with non-cancerous conditions, making this test highly accurate. EasyCheck360® can detect CTCs in almost all types of cancer, including early stages (Stage 0, I, and II), in both men and women. By providing reliable results, this test helps your doctor make timely and informed decisions about your health, giving you the best chance for early diagnosis and potentially curative treatment.
Enabling Proactive, Real-Time Clinical Decisions
Simple blood collection with no surgery, hospitalization, or invasive diagnostic procedures
Detect cancer-associated circulating tumor cells before symptoms appear, supporting timely medical evaluation
Assess cancer risk through a convenient blood test without invasive procedures or complex preparation
Validated for assessing the risk of presence of 30 types of carcinomas through a single blood test
Advanced Cellular Detection for Early Health Insights
Screens blood samples for Circulating Tumor Cells (CTCs) and CTC Clusters associated with underlying carcinomas
Provides lower, moderate, or higher risk assessment based on the presence of cancer-associated cells in blood
Uses immunocytochemistry-based evaluation of tumor-associated cellular markers for characterization of detected cells
A simple, non-invasive screening test designed for asymptomatic individuals aged 30 years and above
Risk-Based Insights from Circulating Tumor Cell Analysis
Assessment of risk of presence of 30 carcinoma types using circulating tumor cell (CTC) detection in blood.Treatment Monitoring
Classification into lower, moderate, or higher risk categories.
Marker expression may suggest probable organ of origin.
Conventional diagnosis often relies on imaging and symptomatic presentation, which may not detect underlying disease at an early stage. EasyCheck360® provides a blood-based assessment of circulating tumor cells (CTCs), offering risk-based insights that support timely clinical evaluation and follow-up decision-making.
Quick peripheral blood collection — no tissue, no invasive procedures
Detection of live tumor signals including CTCs and circulating nucleic acids
Immunocytochemistry evaluation using epithelial and tumor-associated markers
Structured report presenting cancer detection for clinical interpretation